Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent

被引:42
作者
Matsuyama, Takahiro [1 ]
Morita, Takahiro [1 ]
Horikiri, Yuji [1 ]
Yamahara, Hiroshi [1 ]
Yoshino, Hiroyuki [1 ]
机构
[1] Tanabe Seiyaku Co Ltd, CMC Res Labs, Dept Pharmaceut Technol, Yodogawa Ku, Osaka 5328505, Japan
关键词
nasal absorption; absorption enhancement; powdery formulation; mucolytic agent; salmon calcitonin;
D O I
10.1016/j.jconrel.2006.08.004
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
To establish a new formulation technology for the nasal delivery of peptide and protein drugs, we examined whether a mucolytic agent, Nacetyl-L-cysteine (NAC), could enhance the nasal absorption of a powder form of salmon calcitonin, a model peptide drug. We used ethylcellulose as an inert water-insoluble excipient. Various test formulations were prepared, and the effects on nasal absorbability were evaluated in rats and dogs. The powder formulation with NAC gave significant nasal absorption of SCT in both animal models, with absolute bioavailabilities of 30.0% in rats and 24.9% in dogs. Also, nasal administration of this formulation gave a quicker absorption rate than subcutaneous administration of SCT. NAC may reduce nasal fluid viscocity and improve accessibility of the drug to the epithelial membrane. The powder SCT/NAC/ethylcellulose formulation did not induce irritation or histological damage to the nasal membrane in rabbits. These results suggest that this formulation technology may be widely applicable for the nasal delivery of peptide or protein drugs. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 31 条
[1]   Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol [J].
Bagger, MA ;
Nielsen, HW ;
Bechgaard, E .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2001, 14 (01) :69-74
[2]   Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability [J].
Callens, C ;
Pringels, E ;
Remon, JP .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 250 (02) :415-422
[3]   Absorption enhancers for nasal drug delivery [J].
Davis, SS ;
Illum, L .
CLINICAL PHARMACOKINETICS, 2003, 42 (13) :1107-1128
[4]   Delivery of nasal powders of beta-cyclodextrin by insufflation [J].
DeAscentiis, A ;
Bettini, R ;
Caponetti, G ;
Catellani, PL ;
Peracchia, MT ;
Santi, P ;
Colombo, P .
PHARMACEUTICAL RESEARCH, 1996, 13 (05) :734-738
[5]  
Dorato Michael A., 1994, V62, P345
[6]  
GARMISE RJ, 2006, AAPS PHARMSCITECH, V10, pE19
[7]  
GIZURARSON S, 1990, ACTA PHARM NORDICA, V2, P105
[8]  
HIRAI S, 1981, INT J PHARM, V9, P173
[9]  
Hosoya K, 1999, BIOL PHARM BULL, V22, P1089
[10]   HYDROLYSIS OF LEUCINE ENKEPHALIN IN THE NASAL CAVITY OF THE RAT - A POSSIBLE FACTOR IN THE LOW BIOAVAILABILITY OF NASALLY ADMINISTERED PEPTIDES [J].
HUSSAIN, A ;
FARAJ, J ;
ARAMAKI, Y ;
TRUELOVE, JE .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 133 (03) :923-928